Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
309,428
result(s) for
"Protocols"
Sort by:
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Lenvatinib plus either pembrolizumab or everolimus was compared with sunitinib as first-line therapy for advanced renal cell cancer. Progression-free survival was significantly longer with lenvatinib plus pembrolizumab than with sunitinib. Lenvatinib plus everolimus was also more effective than sunitinib, but the difference was smaller.
Journal Article
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
In a randomized trial of bortezomib, cyclophosphamide, and dexamethasone as compared with the same therapy plus daratumumab, patients with light-chain amyloidosis who received daratumumab had a higher frequency of hematologic complete response than those who did not (53.3% vs. 18.1%). Deaths were most commonly due to cardiac failure.
Journal Article
Psilocybin and Motor Function: A Triple‐Blind, Dose‐Finding Study in Healthy Participants
Background
There has been a resurgence of research into the potential therapeutic benefits of psychedelics for neuropsychiatric disorders. Classic psychedelics, such as psilocybin, exert complex effects on higher cognitive functions such as perception and awareness, but their impact on motor function remains unexplored. Moreover, there is a theoretical rationale for using psychedelics to promote motor retraining in certain neuropsychiatric conditions associated with motor dysfunction. This protocol paper outlines the first study to investigate the feasibility and safety of performing movement tasks during the acute effects of psilocybin in healthy participants. The findings from this study will further our understanding of the impact of psychedelics on motor function, and inform future studies that combine classic psychedelics with motor retraining in clinical populations.
Methods
12 healthy participants will each receive three doses of psilocybin (between 5 and 20 mg) in a randomized order, with each dose administered at least 1 week apart. Participants, the trial physiotherapists, and statisticians will remain blinded to the psilocybin dose. A battery of measures assessing motor function will be completed during the acute drug effects. In addition, measures of safety, pre‐ and post‐dose resting‐state brain activity via functional magnetic resonance imaging, and participants' subjective experience will be assessed.
Highlights
Psychedelics may promote motor retraining in certain neuropsychiatric disorders.
No clinical studies have investigated the impact of psychedelics on motor function.
This study will assess the performance of movement tasks during the acute effects of psilocybin in healthy participants.
This will inform the design of a follow‐up study of psilocybin‐assisted physiotherapy in motor functional neurological disorder.
The findings will inform future trials exploring psychedelics to assist motor retraining in other neuropsychiatric disorders with associated motor dysfunction.
Journal Article
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
More than half of breast cancers express low levels of HER2. In a phase 3 trial, the antibody–drug conjugate trastuzumab deruxtecan resulted in longer survival than the physician’s choice of chemotherapy among patients with HER2-low breast cancer.
Journal Article
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater improvement in quality of life measures than standard chemotherapy in patients with
ALK
-positive lung cancer.
Rearrangements of the anaplastic lymphoma kinase (
ALK
) gene are present in 3 to 5% of non–small-cell lung cancers (NSCLCs).
1
,
2
They define a distinct subgroup of NSCLC that typically occurs in younger patients who have never smoked or have a history of light smoking and that has adenocarcinoma histologic characteristics.
3
–
5
Crizotinib is an oral small-molecule tyrosine kinase inhibitor of ALK, MET, and ROS1 kinases.
6
In phase 1 and 2 studies, crizotinib treatment resulted in objective tumor responses in approximately 60% of patients with
ALK
-positive NSCLC and in progression-free survival of 7 to 10 months.
7
–
9
In . . .
Journal Article